Post Profile






Martha Rosenberg: FDA Critic Stripped of Voting Rights at Birth Control Pill Hearings

Bayer launched Yaz in 2006 as a pill that goes "beyond birth control" to treat acne and severe PMS, all the while avoiding the water retention of traditional birth control pills. But soon, previously-healthy teenagers experienced "beyond birth control" effects they hadn't expected.
read more

share
See more about: Birth Control

Related Posts


FDA Reviews Popular Birth Control Pills for Blood Clot Risk

Health : Time: Healthland

The Food and Drug Administration (FDA) said it is reviewing the safety of birth control pills like Bayer's Yaz and Yasmin because of concerns that they may raise women's risk of blood clots more than other pills. Although all hormon...

Bayer Birth Control Pills & $3K Gallbladder Removals

Medical / Pharmaceutical : Pharmalot

After several years of litigation, Bayer Healthcare Pharmaceuticals has agreed to pay $24 million to settle lawsuits claiming that its Yaz and Yasmin birth control pills caused gallbladder disease, according to court documents. As p...

FDA Forces Pharma Company To Admit That Its Birth Control Pill Isn't Miraculous [Advertising]

Lifestyle / Shopping : The Consumerist

Bayer, the company that makes the popular birth control pill, Yaz, is being forced to run ads that "correct" some of the claims that it made in commercials touting the pill's "proven" ability to rid women of acne and PMS. The compan...

Bayer Off-Label Promotion Of Yasmin Birth Control Pill Killed Our Daughter: Lawsuit

Medical / Pharmaceutical : Pharmalot

The thousands of lawsuits filed against Bayer over alleged injuries and deaths relating to the Yaz and Yasmin contraceptives typically dwell on higher risks beyond those of traditional birth control pills and overly aggressively pro...

A Conflicted FDA Panel, Bayer & Birth Control Pills

Medical / Pharmaceutical : Pharmalot

Last month, an FDA advisory committee voted 15-to-11 that the benefits of the Yaz and Yasmin birth control pills outweigh the risks, and so the drugs should remain on the market, albeit with added information about the risk of blood...

Comments


Copyright © 2016 Regator, LLC